CXCL14 and neoplasm: These results indicated that CXCL14 expression could be a good predictive biomarker for cetuximab-dependent tumor suppression and that evaluation of CXCL14 expression could be useful for discrimination of cetuximab-susceptible and -resistant carcinomas, thereby benefiting patients by potentially reducing treatment time and costs.